Posted by Michael Wonder on 25 Mar 2017
European Medicines Agency’s CHMP recommends approval of Merck’s Keytruda (pembrolizumab) for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma
24 March 2017 - Recommendation Is for adult patients who have failed autologous stem cell transplant and brentuximab vedotin or who are transplant ineligible and have failed brentuximab vedotin.
Merck announced today that the CHMP of the EMA has adopted a positive opinion recommending approval of Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin or who are transplant-ineligible and have failed brentuximab vedotin.
The recommendation will now be reviewed by the European Commission for marketing authorisation in the European Union. A decision on approval is expected in the second quarter of 2017.
